Monocyte type i interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use

Annals of the Rheumatic Diseases

Volumn 75, Issue 12, 2016, Pages

  Van Den Hoogen, Lucas L ^a   Fritsch Stork, Ruth D E ^a,b,c   Versnel, Marjan A ^d   Derksen, Ronald H W M ^a   Van Roon, Joël A G ^a   Radstake, Timothy R D J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c SIGMUND FREUD UNIVERSITY   (Austria)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiphospholipid Syndrome; Autoimmune Diseases; Cytokines; Inflammation; Systemic Lupus Erythematosus

Indexed keywords

HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CELL DIFFERENTIATION; CELL SUBPOPULATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; ENDOTHELIAL PROGENITOR CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MONOCYTE; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONOCYTES;

EID: 84991712940     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210485     Document Type: Letter

References (12)

1. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
2. Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69.
3. Grenn RC, Yalavarthi S, Gandhi AA, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis 2016; Published Online First 18 July 2016.
4. van den Hoogen LL, van Roon JAG, Radstake TRDJ, et al. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev 2016;15:50-60.
5. Bernales I, Fullaondo A, Marín-Vidalled MJ, et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 2008;9:38-46.
6. Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015;74:1441-9.
7. Mikoajczyk TP, Osmenda G, Batko B, et al. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 2016;25:18-27.
8. Winchester R, Giles JT, Nativ S, et al. Association of Elevations of Specific T Cell and Monocyte Subpopulations in Rheumatoid Arthritis with Subclinical Coronary Artery Atherosclerosis. Arthritis Rheum 2016;68:92-102.
9. Derksen RH, Gmelig-Meijling FH, de Groot PG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus 1996;5:77-80.
10. Abraham Simón J, Rojas-Serrano J, Cabiedes J, et al. Antinucleosome antibodies May help predict development of systemic lupus erythematosus in patients with primary antiphospholipid syndrome. Lupus 2004;13:177-81.
11. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-96.
12. Brkic Z, Corneth OB, van Helden-Meeuwsen CG, et al. T helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus Arthritis Res Ther 2014;16:R62.